1. Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study
- Author
-
Sebastian Søby, Anita Gothelf, Niels Gyldenkerne, Jens Bentzen, Kinga Nowicka-Matus, Trine Tramm, and Jesper Grau Eriksen
- Subjects
Squamous Cell Carcinoma of Head and Neck ,palliative treatment ,Head and Neck Neoplasms/drug therapy ,Hematology ,General Medicine ,national data ,Cohort Studies ,Neoplasm Recurrence, Local/drug therapy ,Nivolumab ,Oncology ,Head and Neck Neoplasms ,Squamous Cell Carcinoma of Head and Neck/drug therapy ,Humans ,Radiology, Nuclear Medicine and imaging ,immunotherapy ,Neoplasm Recurrence, Local ,Head and neck cancer ,Aged - Abstract
Introduction: The aim of this study was to investigate phase IV efficacy, of the PD-1 inhibitor nivolumab among an unselected and unbiased national cohort of recurrent/metastatic Head and Neck Squamous Cell Carcinoma (rmHNSCC) patients. Material and Methods: Inclusion criteria included histologically confirmed rmHNSCC and nivolumab as a second-line palliative treatment. Data were collected from patient files at the five Danish head and neck cancer centers and from the DAHANCA database. The iRECIST criteria were used for treatment evaluation. Endpoints were response rate (RR), overall survival (OS), and progression-free survival (PFS), calculated from the start of treatment to the date of event/censoring by the KM-method. Descriptive statistics were used to describe patients and treatment. Analyses were two-sided, with p
- Published
- 2022